Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Non-Current Deferred Tax Liability (2019 - 2023)

Insight Molecular Diagnostics' Non-Current Deferred Tax Liability history spans 3 years, with the latest figure at $2.2 million for Q3 2023.

  • On a quarterly basis, Non-Current Deferred Tax Liability changed N/A to $2.2 million in Q3 2023 year-over-year; TTM through Sep 2023 was $2.2 million, a N/A change, with the full-year FY2019 number at $3.8 million, changed N/A from a year prior.
  • Non-Current Deferred Tax Liability hit $2.2 million in Q3 2023 for Insight Molecular Diagnostics, roughly flat from $2.2 million in the prior quarter.
  • Over the last five years, Non-Current Deferred Tax Liability for IMDX hit a ceiling of $3.8 million in Q4 2019 and a floor of $158000.0 in Q1 2020.
  • Historically, Non-Current Deferred Tax Liability has averaged $1.6 million across 3 years, with a median of $2.2 million in 2023.